Cargando…

Targeted therapies for ER+/HER2- metastatic breast cancer

The majority of breast cancers present with estrogen receptor (ER)-positive and human epidermal growth factor receptor (HER2)-negative features and might benefit from endocrine therapy. Although endocrine therapy has notably evolved during the last decades, the invariable appearance of endocrine res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamamoto-Ibusuki, Mutsuko, Arnedos, Monica, André, Fabrice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462184/ https://www.ncbi.nlm.nih.gov/pubmed/26059247 http://dx.doi.org/10.1186/s12916-015-0369-5

Ejemplares similares

The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer
por: Fujiwara, Saori, et al.
Publicado: (2014)

An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer
por: Sueta, Aiko, et al.
Publicado: (2014)

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?
por: Mery, Benoîte, et al.
Publicado: (2021)

Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
por: Takeshita, Takashi, et al.
Publicado: (2018)

Clinical development of mTOR inhibitors in breast cancer
por: Vicier, Cecile, et al.
Publicado: (2014)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009)

Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
por: Miles, David W
Publicado: (2009)

Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
por: Hackshaw, Michelle D., et al.
Publicado: (2020)

Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer
por: Montagna, Emilia, et al.
Publicado: (2019)

Targeted therapy for HER2 positive breast cancer
por: Incorvati, Jason A, et al.
Publicado: (2013)

Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm
por: Yang, Charlie, et al.
Publicado: (2023)

A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer
por: Yamamoto, Satoko, et al.
Publicado: (2013)

Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review
por: Kandula, Mahesh, et al.
Publicado: (2013)

HER2-targeted therapy influences CTC status in metastatic breast cancer
por: Deutsch, Thomas M., et al.
Publicado: (2020)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

Do body composition parameters correlate with response to targeted therapy in ER+/HER2- metastatic breast cancer patients? Role of sarcopenia and obesity
por: Kripa, Endi, et al.
Publicado: (2022)

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
por: Roßwag, Sven, et al.
Publicado: (2021)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni, Mohamad Adham, et al.
Publicado: (2021)

Current and Emerging Therapies for HER2-Positive Women With Metastatic Breast Cancer
por: Porter, Karlyn, et al.
Publicado: (2017)

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2023)

Emerging Targeted Therapies for HER2-Positive Breast Cancer
por: Mercogliano, María Florencia, et al.
Publicado: (2023)

HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis
por: Erickson, Anders W, et al.
Publicado: (2020)

Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence
por: Sueta, Aiko, et al.
Publicado: (2017)

Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends
por: Vega Cano, Kreina Sharela, et al.
Publicado: (2022)

Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy
por: Omoto, Yoko, et al.
Publicado: (2015)

Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
por: Morrow, Phuong Khanh H, et al.
Publicado: (2009)

Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis
por: Wu, Xian-Meng, et al.
Publicado: (2023)

Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer
por: Schlam, Ilana, et al.
Publicado: (2022)

Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
por: Keller, Magdalena, et al.
Publicado: (2023)

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer
por: Chandran, Vineesh Indira, et al.
Publicado: (2015)

A progressive and refractory case of breast cancer with Cowden syndrome
por: Sueta, Aiko, et al.
Publicado: (2022)

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy
por: Cabel, Luc, et al.
Publicado: (2020)

A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer
por: Alasmari, Moudi M.
Publicado: (2022)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor()
por: Beije, Nick, et al.
Publicado: (2016)

The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
por: Mendes, Diogo, et al.
Publicado: (2015)

Associations Between Elastography Findings and Clinicopathological Factors in Breast Cancer
por: Hayashi, Mitsuhiro, et al.
Publicado: (2015)

Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
por: Tapia, Marta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v0t5sr5m6lmcl13ql21ae5vdmk